Rheumatology Book



Aka: Abatacept, CTLA4-Ig
  1. Mechanism
    1. Extracellular CTLA4 fused to Fc of IgG1
    2. Inhibits CD28 to CD80/CD66 binding
    3. Increases T-Cell Activation threshold and inhibits T-Cell proliferation
  2. Dosing
    1. IV infusion: 10 mg/kg to 500, 750 or 1000 mg over 30 minutes
    2. Initial: 0, 2 and 4 months and then every 4 months
  3. Indications
    1. Refractory Rheumatoid Arthritis
  4. Contraindications
    1. Do not use with TNF Antagonist agent, and probably Anankira
    2. Live virus Vaccine within the last 3 months

abatacept (C1619966)

Definition (NCI) A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.
Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSH C468566
SnomedCT 421412005, 421777009
English Abatacept, Abatacept (product), Abatacept (substance), abatacept, ABATACEPT, abatacept (medication), abatacept [Chemical/Ingredient]
Spanish abatacept (sustancia), abatacept (producto), abatacept
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree